Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Nagafuji, Koji  [Clear All Filters]
2024
Mori Y, Takizawa J, Katsuoka Y, Takezako N, Nagafuji K, Handa H, Kuroda J, Sunami K, Kamimura T, Ogawa R, et al. Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer Sci. 2024.
Onozawa M, Kusumoto S, Najima Y, Hashimoto H, Okada K, Tamaki M, Tanaka M, Sato T, Takahashi T, Hatano K, et al. Outcomes of cessation of the administration of nucleos(t)ide analogues on HBV reactivation after allogeneic hematopoietic stem cell transplantation: A nationwide retrospective study. Transplant Cell Ther. 2024.
Nakaya Y, Nakamae H, Nishikubo M, Kondo E, Fukuda T, Hiramoto N, Mori Y, Nagafuji K, Eto T, Onishi Y, et al. Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma. Bone Marrow Transplant. 2024.
Shibata S, Arai Y, Kondo T, Mizuno S, Yamasaki S, Akasaka T, Doki N, Ota S, Maruyama Y, Matsuoka K-I, et al. Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia. Cytotherapy. 2024.
Takaki Y, Yanai T, Shibata T, Honma T, Otsuka M, Yamasaki Y, Oya S, Nakamura T, Maehiro Y, Yamaguchi M, et al. [Successful induction therapy for acute myeloid leukemia under management with extracorporeal membrane oxygenation]. Rinsho Ketsueki. 2024;65(5):330-334.
2023
Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida S-I, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, et al. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs. Haematologica. 2023.
Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, et al. Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide. Bone Marrow Transplant. 2023.
Nagafuji K. [Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in the first complete remission]. Rinsho Ketsueki. 2023;64(9):1144-1151.
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka K-I, et al. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2023.
2019
Morishima Y, Morishima S, Murata M, Arima N, Uchida N, Sugio Y, Takahashi S, Matsuhashi Y, Onizuka M, Eto T, et al. Impact of homozygous conserved extended HLA haplotype on single cord blood transplantation: Lessons for induced pluripotent stem cell banking and transplantation in allogeneic settings. Biol Blood Marrow Transplant. 2019.
2016
Murayama T, Fukuda T, Okumura H, Sunami K, Sawazaki A, Maeda Y, Tsurumi H, Uike N, Hidaka T, Takatsuka Y, et al. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04. Int J Hematol. 2016.
2014
Kawaguchi K, Nakamura T, Nohara M, Koteda S, Nomura K, Morishige S, Oku E, Imamura R, Mouri F, Seki R, et al. Donor-derived 47, XXY in an unrelated cord blood transplant recipient. Springerplus. 2014;3:72.
2013
Eto T, Takase K, Miyamoto T, Ohno Y, Kamimura T, Nagafuji K, Takamatsu Y, Teshima T, Gondo H, Taniguchi S, et al. Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission. Int J Hematol. 2013.